Considering the aggressive variability of prostate cancer (PCa) and the wide range of available treatments, European guidelines recommend different treatment options according to prognostic risk stratification.1 However, to date there’s no consensus about which is the best timeframe for such tumour to provide treatment and if different risk classes might have reserved different timing for treatment.